{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:54:26Z","timestamp":1792079666449,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.3816\/clml.2010.n.065","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T23:44:49Z","timestamp":1289432689000},"page":"331-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia"],"prefix":"10.3816","volume":"10","author":[{"given":"Rishard","family":"Salie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.065_bib1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLML.2010.n.065_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/asheducation-2002.1.111","article-title":"Chronic myelogenous leukemia","author":"Druker","year":"2002","journal-title":"Blood (Am Soc Hematol Educ Program)"},{"key":"10.3816\/CLML.2010.n.065_bib3","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.065_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","article-title":"Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature","volume":"33","author":"Guastafierro","year":"2009","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.065_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib8","doi-asserted-by":"crossref","first-page":"130a","DOI":"10.1182\/blood.V108.11.428.428","article-title":"Six-year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukemia (CML) post interferon-A (IFN) refractoriness\/intolerance","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.V112.11.2126.2126","article-title":"Imatinib frontline therapy is safe and effective in patients with chronic myeloid leukemia (CML) with liver and\/or renal dysfunction","volume":"112","author":"Tong","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib10","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib12","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"10.3816\/CLML.2010.n.065_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1211\/jpp.58.4.0017","article-title":"Cardiotoxic effects of arsenic trioxide\/imatinib mesilate combination in rats","volume":"58","author":"Saad","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.3816\/CLML.2010.n.065_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.leukres.2008.03.020","article-title":"An evaluation of the cardiotoxicity of imatinib mesylate","volume":"32","author":"Ribeiro","year":"2008","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.065_bib16","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","article-title":"Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005","volume":"43","author":"Verweij","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLML.2010.n.065_bib17","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"10.3816\/CLML.2010.n.065_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ajh.10186","article-title":"Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia","volume":"71","author":"Barton","year":"2002","journal-title":"Am J Hematol"},{"key":"10.3816\/CLML.2010.n.065_bib19","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(02)08616-6","article-title":"Cerebral oedema as a possible complication of treatment with imatinib","volume":"359","author":"Ebnoether","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CLML.2010.n.065_bib20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.leukres.2004.03.007","article-title":"Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms","volume":"28","author":"Bruck","year":"2004","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.065_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2003.01.052","article-title":"Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia","volume":"21","author":"Ramar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.065_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/cncr.10729","article-title":"Severe periorbital edema secondary to STI571 (Gleevec)","volume":"95","author":"Esmaeli","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.065_bib23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/sj.eye.6701315","article-title":"Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)","volume":"18","author":"Esmaeli","year":"2004","journal-title":"Eye (Lond)"},{"key":"10.3816\/CLML.2010.n.065_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/00043426-200211000-00020","article-title":"Unexpected pleural effusions in 3 pediatric patients treated with STI-571","volume":"24","author":"Goldsby","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.3816\/CLML.2010.n.065_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0609.2004.00347.x","article-title":"Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib","volume":"74","author":"Breccia","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1600-0609.2006.00649.x","article-title":"Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia","volume":"76","author":"Moore","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/108076803322279426","article-title":"Ocular side-effects associated with imatinib mesylate (Gleevec)","volume":"19","author":"Fraunfelder","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.3816\/CLML.2010.n.065_bib28","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2403364","article-title":"Visual disturbance due to retinal edema as a complication of imatinib","volume":"18","author":"Kusumi","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.065_bib29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10384-008-0561-7","article-title":"Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)","volume":"52","author":"Kwon","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"10.3816\/CLML.2010.n.065_bib30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.3816\/CLML.2010.n.065_bib31","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1345\/aph.1G131","article-title":"Acute renal failure secondary to imatinib mesylate treatment in prostate cancer","volume":"39","author":"Foringer","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.3816\/CLML.2010.n.065_bib32","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.065_bib33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.ajkd.2007.10.039","article-title":"Partial Fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss","volume":"51","author":"Francois","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.3816\/CLML.2010.n.065_bib34","first-page":"627","article-title":"Imatinib and altered bone and mineral metabolism [erratum published in: N Engl J Med 2006; 355:1627]","volume":"355","author":"Tournis","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.065_bib35","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1056\/NEJMc062388","article-title":"Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism","volume":"355","author":"Grey","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.065_bib36","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.065_bib37","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients","volume":"111","author":"Fitter","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.065_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-0609.2004.00351.x","article-title":"Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib","volume":"74","author":"Breccia","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib39","first-page":"228","article-title":"Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate","volume":"5","author":"Scheinfeld","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.3816\/CLML.2010.n.065_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLML.2010.n.065_bib41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2002.03499.x","article-title":"Stevens-Johnson syndrome after treatment with STI571: a case report","volume":"117","author":"Hsiao","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib42","first-page":"285","article-title":"Imatinib mesylate-induced maculopapular drug rash","volume":"16","author":"Dogra","year":"2003","journal-title":"Natl Med J India"},{"key":"10.3816\/CLML.2010.n.065_bib43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000073102","article-title":"Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign","volume":"207","author":"Banka","year":"2003","journal-title":"Dermatology"},{"key":"10.3816\/CLML.2010.n.065_bib44","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1345\/aph.1D184","article-title":"Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing","volume":"37","author":"Tanvetyanon","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.3816\/CLML.2010.n.065_bib45","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1034\/j.1600-0609.2002.02830.x","article-title":"Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia","volume":"69","author":"Schwarz","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/0378-6323.16628","article-title":"Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose","volume":"71","author":"Pavithran","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.3816\/CLML.2010.n.065_bib47","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-2141.2002.37133.x","article-title":"Sti571-induced Stevens-Johnson Syndrome","volume":"119","author":"Vidal","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib48","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.0303-6987.2003.053.x","article-title":"Mycosis fungoides-like reaction in a patient treated with Gleevec","volume":"30","author":"Clark","year":"2003","journal-title":"J Cutan Pathol"},{"key":"10.3816\/CLML.2010.n.065_bib49","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2141.2006.06046.x","article-title":"Effective treatment of a case of refractory mycosis fungoides with imatinib","volume":"133","author":"Oka","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib50","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1002\/cncr.11812","article-title":"Imatinib mesylate causes hypopigmentation in the skin","volume":"98","author":"Tsao","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.065_bib51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4103\/0378-6323.16627","article-title":"Lichenoid eruption due to imatinib","volume":"71","author":"Prabhash","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.3816\/CLML.2010.n.065_bib52","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/00015550310012593","article-title":"Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate","volume":"83","author":"Pasmatzi","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.3816\/CLML.2010.n.065_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.leu.2403115","article-title":"Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia","volume":"18","author":"Breccia","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.065_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2003.04277.x","article-title":"Precipitation of porphyria cutanea tarda by imatinib mesylate?","volume":"121","author":"Ho","year":"2003","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.065_bib55","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0145-2126(03)00257-1","article-title":"Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate","volume":"28","author":"Liu","year":"2004","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.065_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.leukres.2004.05.015","article-title":"Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy","volume":"29","author":"Dib","year":"2005","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.065_bib57","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1034\/j.1600-0609.2003.00044.x","article-title":"Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment","volume":"70","author":"Baskaynak","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.065_bib58","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2003-07-2436","article-title":"EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate","volume":"102","author":"Bekkenk","year":"2003","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011701987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011701987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:14Z","timestamp":1761870194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011701987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S2152265011701987"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.065","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}